Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 HTX-019: Polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxisFuture Oncology.  15:241-255. 2019
2019 Integrating geriatric assessment into routine gastrointestinal (GI) consultation: The Cancer and Aging Resilience Evaluation (CARE)Journal of Geriatric Oncology2019
2018 Should palonosetron be a preferred 5-HT 3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysisSupportive Care in Cancer.  26:2519-2549. 2018
2018 Phase III safety study of intravenous NEPA: A novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapyAnnals of Oncology.  29:1535-1540. 2018
2018 Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapyCancer Medicine.  7:2943-2950. 2018
2018 Safety of Polysorbate 80 in the Oncology SettingAdvances in Therapy.  35:754-767. 2018
2018 Managing Nausea and Vomiting in Patients With Cancer: What WorksOncology.  32. 2018
2018 Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomitingOncoTargets and Therapy.  11:6459-6478. 2018
2017 Thalidomide: Rebirth of a gestational antiemetic?Journal of Clinical Oncology.  35:3523-3524. 2017
2017 Recent developments in the clinical pharmacology of rolapitant: Subanalyses in specific populationsDrug Design, Development and Therapy.  11:2621-2629. 2017
2017 Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric PatientsPediatric Drugs.  19:213-222. 2017
2017 2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk ChemotherapySupportive Care in Cancer.  25:277-288. 2017
2017 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomitingSupportive Care in Cancer.  25:303-308. 2017
2017 Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapySupportive Care in Cancer.  25:85-92. 2017
2016 The authors replyNew England Journal of Medicine.  375:1396. 2016
2016 Rolapitant hydrochloride: Prophylactic treatment for chemotherapy-induced nausea and vomitingDrugs of Today.  52:431-438. 2016
2016 Olanzapine for the prevention of chemotherapy-induced nausea and vomitingNew England Journal of Medicine.  375:134-142. 2016
2016 Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysisSupportive Care in Cancer.  24:2381-2392. 2016
2016 Antiemetic prophylaxis for chemotherapy-induced nausea and vomitingNew England Journal of Medicine.  374:1356-1367. 2016
2016 Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapyEuropean journal of cancer.  57:23-30. 2016
2016 Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomitingThe Journal of community and supportive oncology.  14:141-147. 2016
2016 The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomitingExpert Opinion on Drug Safety.  15:343-356. 2016
2016 Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic reviewSupportive Care in Cancer.  24:1001-1008. 2016
2015 5-HT3receptors as important mediators of nausea and vomiting due to chemotherapyBBA - Biomembranes.  1848:2738-2746. 2015
2015 Rolapitant for the treatment of chemotherapy-induced nausea and vomitingExpert Review of Anticancer Therapy.  15:1127-1133. 2015
2015 Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: Two randomised, active-controlled, double-blind, phase 3 trialsLancet Oncology.  16:1079-1089. 2015
2015 Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: A randomised, active-controlled, double-blind, phase 3 trialLancet Oncology.  16:1071-1078. 2015
2015 Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and VomitingBioMed Research International.  2015. 2015
2014 Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)Drug Design, Development and Therapy.  9:155-161. 2014
2014 Clinical roundtable monograph: New data in emerging treatment options for chemotherapy-induced nausea and vomitingClinical Advances in Hematology and Oncology.  12:1-15. 2014
2014 Clinical roundtable monograph: New data in emerging treatment options for chemotherapy-induced nausea and vomiting.Clinical Advances in Hematology and Oncology.  12:1-14. 2014
2014 Clinical trial data in chemotherapy-induced nausea and vomitingClinical Advances in Hematology and Oncology.  12:5-8. 2014
2014 Clinical trial data in chemotherapy-induced nausea and vomiting.Clinical Advances in Hematology and Oncology.  12 Suppl 9:5-8. 2014
2014 Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomitingEuropean Journal of Pharmacology.  722:180-186. 2014
2014 Palonosetron for the treatment of chemotherapy-induced nausea and vomitingExpert Opinion on Pharmacotherapy.  15:2599-2608. 2014
2013 Selective photocrosslinking of functional ligands to antibodies viatheconserved nucleotide binding siteBiomaterials.  34:5700-5710. 2013
2013 The current status of the use of palonosetronExpert Opinion on Pharmacotherapy.  14:1281-1284. 2013
2013 The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapySupportive Care in Cancer.  21:1655-1663. 2013
2013 Management of chemotherapy-induced nausea and vomiting: Focus on newer agents and new uses for older agentsDrugs.  73:249-262. 2013
2012 A Review of the prevention of nausea and vomiting induced by chemotherapyEuropean oncology & haematology.  9:51-55. 2012
2012 Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivoBlood Cancer Journal.  2. 2012
2012 Treatment of chemotherapy-induced nauseaCommunity Oncology.  9:20-26. 2012
2011 Blood component therapy in trauma guided with the utilization of the perfusionist and thromboelastographyJournal of Extra-corporeal Technology.  43:162-167. 2011
2011 Olanzapine Versus Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized Phase III TrialJournal of Supportive Oncology.  9:188-195. 2011
2011 An accompanying genetic severe deficiency of tissue factor protects mice with a protein C deficiency from lethal endotoxemiaBlood.  117:283-289. 2011
2010 Treatment of cancer-related anorexia with olanzapine and megestrol acetate: A randomized trialSupportive Care in Cancer.  18:951-956. 2010
2010 Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancerFuture Oncology.  6:1073-1084. 2010
2009 Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy.Cancer Management and Research.  1:167-176. 2009
2009 Palonosetron: A second generation 5-hydroxytryptamine 3 receptor antagonist Palonosetron NavariExpert Opinion on Drug Metabolism and Toxicology.  5:1577-1586. 2009
2009 Treatment of chemotherapy-induced breakthrough nauea and vomiting.Journal of Clinical Oncology.  27:e20536. 2009
2009 Pharmacological management of chemotherapy-induced nausea and vomitingDrugs.  69:515-533. 2009
2009 Antiemetic control: Toward a new standard of care for emetogenic chemotherapyExpert Opinion on Pharmacotherapy.  10:629-644. 2009
2008 Fosaprepitant: A neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomitingExpert Review of Anticancer Therapy.  8:1733-1742. 2008
2008 Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapyBreast Cancer Research and Treatment.  112:197-201. 2008
2008 Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and antinausea activitiesCurrent Opinion in Investigational Drugs.  9:774-785. 2008
2008 Treatment of cancer-related anorexia with olanzapine and megestrol acetate.Journal of Clinical Oncology.  26:9576. 2008
2007 Fosaprepitant (MK-0517): A neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomitingExpert Opinion on Investigational Drugs.  16:1977-1985. 2007
2007 A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier oncology group studySupportive Care in Cancer.  15:1285-1291. 2007
2007 Overview of the updated antiemetic guidelines for chemotherapy-induced nausea and vomitingCommunity Oncology.  4:3-11. 2007
2007 Prevention of emesis from multiple-day and high-dose chemotherapy regimensJournal of the National Comprehensive Cancer Network.  5:51-59. 2007
2006 Palonosetron: A second-generation 5-hydroxytryptamine receptor antagonistFuture Oncology.  2:591-602. 2006
2006 A phase II trial of olanzapine and palonosetron for the prevention of chemotherapy induced nausea and vomiting (CINV).Journal of Clinical Oncology.  24:8608. 2006
2006 Emerging drugs for chemotherapy-induced emesisExpert Opinion on Emerging Drugs.  11:137-151. 2006
2006 New approaches to chemotherapy-induced nausea and vomiting: From neuropharmacology to clinical investigationsCancer Journal.  12:341-347. 2006
2006 Ondansetron, prochlorperazine, and dexamethasone have similar effects on prevention of delayed chemotherapy-induced nausea and vomitingCancer Treatment Reviews.  32:50-54. 2006
2005 Cathepsin E is a specific marker of dysplasia in APC Min/+ mouse intestineTumor Biology.  27:36-42. 2005
2005 Symptomatic treatment of infections in patients with advanced cancer receiving hospice careJournal of Pain and Symptom Management.  30:175-182. 2005
2005 A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group studySupportive Care in Cancer.  13:529-534. 2005
2005 Symptomatic treatment of infections in patients with advanced cancer receiving hospice care.Journal of Clinical Oncology.  23:8069. 2005
2004 Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: Summary of clinical trialsCancer Investigation.  22:569-576. 2004
2004 A phase I trial of olanzapine (zyprexa) for the prevention of delayed emesis in cancer patients: A hoosier oncology group studyCancer Investigation.  22:383-388. 2004
2004 A phase II trial of olanzapine for the prevention of chemotherapy induced nausea and vomiting (CINV).Journal of Clinical Oncology.  22:8046. 2004
2004 The anti-ischemia agent ranolazine promotes the development of intestinal tumors in APC (Min/+) miceCancer Letters.  209:165-169. 2004
2004 Aprepitant: A neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomitingExpert Review of Anticancer Therapy.  4:715-724. 2004
2004 Inhibiting substance p pathway for prevention of chemotherapy-induced emesis: preclinical data, clinical trials of neurokinin-1 receptor antagonists.Supportive Cancer Therapy.  1:89-96. 2004
2003 Comment: Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine-3 receptor antagonists [6] (multiple letters)Annals of Pharmacotherapy.  37:1918-1919. 2003
2003 Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonistsAnnals of Pharmacotherapy.  37:1276-1286. 2003
2003 Antimicrobial use in patients with advanced cancer receiving hospice careJournal of Pain and Symptom Management.  25:438-443. 2003
2003 Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.Journal of Supportive Oncology.  1:89-103. 2003
2002 Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869: A randomized controlled trialCancer.  94:3032-3041. 2002
2002 Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinomaCancer.  94:25-36. 2002
2001 International study in premedical educationAcademic Medicine.  76:1158. 2001
2000 Preferences of patients with advanced cancer for hospice care [2]Journal of the American Medical Association.  284:2449. 2000
1999 Prevention of cisplatin-induced emesis by a neurokinin-1-receptor antagonist [4] (multiple letters)New England Journal of Medicine.  340:1926-1928. 1999
1999 Reduction of cisplatin-induced emesis by a selective neurokinin-1- receptor antagonistNew England Journal of Medicine.  340:190-195. 1999
1999 A prisoner with chronic myeloid leukemiaBone Marrow Transplantation.  24:1037-1039. 1999
1999 Use of placebos in delayed-emesis studies [6] (multiple letters)Journal of Clinical Oncology.  17:1648-1650. 1999
1998 Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapyJournal of Clinical Oncology.  16:1568-1573. 1998
1997 The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapyAnnals of Oncology.  8:181-185. 1997
1997 Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesisSupportive Care in Cancer.  5:31-37. 1997
1997 Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapyCancer Investigation.  15:297-303. 1997
1997 Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapyJournal of Clinical Oncology.  15:2966-2973. 1997
1997 Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasoneJournal of Clinical Oncology.  15:2135-2138. 1997
1996 Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinomaCancer.  78:789-793. 1996
1996 Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancerJournal of Clinical Oncology.  14:2242-2249. 1996
1996 Is oral ondansetron really efficacious in the control of cisplatin- induced delayed emesis? [1]Journal of Clinical Oncology.  14:1401-1402. 1996
1995 Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesisJournal of Clinical Oncology.  13:1242-1248. 1995
1995 Oral ondansetron for the control of cisplatin-induced delayed emesis: A large, multicenter, double-blind, randomized comparative trial of ondansetron versus placeboJournal of Clinical Oncology.  13:2408-2416. 1995
1994 Treatment of cancer-associated hypercalcemia: Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline aloneArchives of Internal Medicine -New Series-.  154:1935-1944. 1994
1994 Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatinJournal of Clinical Oncology.  12:2204-2210. 1994
1993 Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapyCancer.  72:583-586. 1993
1993 Protein turnover in advanced lung cancer patientsMetabolism.  42:291-296. 1993
1992 Glucose metabolism in advanced lung cancer patients.Nutrition.  8:245-251. 1992
1992 Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomitingJournal of Clinical Oncology.  10:1969-1975. 1992
1991 Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitorJournal of Clinical Endocrinology and Metabolism.  73:99-106. 1991
1989 Comparison of intermittent versus continuous infusion metoclopramide in control of acute nausea induced by cisplatin chemotherapyJournal of Clinical Oncology.  7:943-946. 1989
1987 Treatment of marrow graft recipients with thymopentinBone Marrow Transplantation.  1:365-371. 1987
1986 Laminar air flow isolation and decontamination: A prospective randomized study of the effects of prophylactic systemic antibiotics in bone marrow transplant patientsInfection.  14:115-121. 1986
1984 Hypothermia.The Alabama journal of medical sciences.  21:374-381. 1984
1984 Prophylaxis of infection in patients with aplastic anemia receiving allogeneic marrow transplantsAmerican Journal of Medicine.  76:564-572. 1984
1983 Pneumatosis cystoides intestinalis following allogeneic marrow transplantationTransplantation Proceedings.  15:1720-1724. 1983
1983 The peripheral blood smear in heat stroke. An aid to diagnosis.The Alabama journal of medical sciences.  20:137-140. 1983
1983 Bone marrow necrosis in acute leukemiaActa Haematologica.  69:158-163. 1983
1983 Mycobacterial infections in marrow transplant patientsTransplantation.  36:509-513. 1983
1982 Routine Endoscopy in Upper-Gastrointestinal Tract BleedingNew England Journal of Medicine.  306:869-871. 1982
1981 Renal Adenocarcinoma Associated With Multiple Simple CystsJournal of the American Medical Association.  246:1808-1809. 1981
1980 Functional, morphological, and metabolic abnormalities of the cerebral microcirculation after concussive brain injury in catsCirculation Research.  46:37-47. 1980
1979 Oxygen consumption of pial arteriesAJP - Heart and Circulatory Physiology.  5. 1979
1979 Oxygen consumption of pial arteries.American Journal of Physiology.  236. 1979
1978 Inhibition of rat bronchiolar oxygen consumption by plasma proteinsJournal of applied physiology: respiratory, environmental and exercise physiology.  44:659-665. 1978
1978 Role of tissue hypoxia in local regulation of cerebral microcirculation.American Journal of Physiology.  234. 1978
1978 Responses of cerebral arteries and arterioles to acute hypotension and hypertension.American Journal of Physiology.  234. 1978
1978 Comparison of the open skull and cranial window preparations in the study of the cerebral microcirculationMicrovascular Research.  16:304-315. 1978
1978 Responses of cerebral arteries and arterioles to acute hypotension and hypertensionAJP - Heart and Circulatory Physiology.  3. 1978
1977 Mass transfer properties of gases in fluorocarbonsResearch in Experimental Medicine.  170:169-180. 1977
1977 Effects of induced acute hypertension on the oxygen consumption and responsiveness of cerebral arteriolesClinical research.  25. 1977
1977 In Vitro Depression of Tissue Oxygen Uptake by Liquid Fluorocarbon Prepared as Artificial BloodProceedings of the Society for Experimental Biology and Medicine.  154:346-350. 1977
1977 Oxygen consumption of pial arteriesFederation proceedings.  36. 1977
1976 Fluorocarbon effects on tissue OO2in vitroFederation proceedings.  35. 1976
1975 Effects of vitamins A and E on rat tissue lipidsNutrition reports international.  11:17-28. 1975
1974 Laboratory experiments using nicotineJournal of Chemical Education.  51:748-750. 1974
1974 Effect of plasma proteins on oxygen diffusion in the pulmonary capillariesMicrovascular Research.  7:120-130. 1974
1971 Transport in human plasma.Aerospace medicine.  42:1123-1124. 1971
1971 A predictive theory for diffusion in polymer and protein solutionsAIChE Journal.  17:1028-1036. 1971
1969 Blood flow modeling with microcapsular suspensionsIndustrial and Engineering Chemistry Fundamentals.  8:615-620. 1969
1968 Prediction of the sigma effect in blood flow.Biorheology.  5:237-239. 1968

Book

Year Title Altmetric
2016 Management of chemotherapy-induced nausea and vomiting: New agents and new uses of current agents 2016

Chapter

Year Title Altmetric
2018 Antiemetics.  587-601. 2018
2016 Clinical management of CINV.  157-162. 2016
2016 Conclusions.  177-178. 2016
2016 Future directions.  179-181. 2016
2016 Introduction.  1-3. 2016
2016 Olanzapine for the prevention of chemotherapy-induced nausea and vomiting.  107-120. 2016
2016 Treatment of chemotherapy-induced nausea.  163-176. 2016

Research Overview

  • Supportive Care in Oncology, Antiemetics
  • Investigator On

  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS 2019 - 2025
  • Private Grant  awarded by CLOVIS ONCOLOGY 2017 - 2022
  • Private Grant  awarded by CLOVIS ONCOLOGY 2017 - 2022
  • Education And Training

  • Doctor of Medicine, Virginia Commonwealth University 1978
  • Doctor of Philosophy in Chemical Engineering, University of Virginia 1971
  • Master of Engineering in Chemical Engineering, University of Virginia 1969
  • Bachelor of Engineering in Chemical Engineering, University of Notre Dame 1967
  • UAB, Internship 1978
  • University of Alabama at Birmingham, Residency 1980
  • University of Alabama at Birmingham, Residency 1978
  • University of Washington School of Medicine and Medical Centers, Postdoctoral Fellowship 1983
  • Full Name

  • Rudolph Navari